Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Часто задаваемые вопросы
В каком секторе работает Aadi Bioscience Inc (AADI)?
Aadi Bioscience Inc относится к сектору Здравоохранение.
Выплачивает ли Aadi Bioscience Inc (AADI) дивиденды?
Нет, Aadi Bioscience Inc не выплачивает дивиденды.